Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 6Thiotepa 5Granulocyte Colony-Stimulating Factor 4Filgrastim 4Etoposide 4Cisplatin 4Busulfan 4tislelizumab 3Melphalan 3Carboplatin 3tazemetostat 2regorafenib 2pembrolizumab 2belinostat 2Topotecan 2Temozolomide 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Mesna 2Ifosfamide 2Doxorubicin 2spartalizumab 1sodium thiosulfate 1sargramostim 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1entinostat 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × OSI 930 × Other solid neoplasm × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡